The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

The Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...

(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...